Thrombolytic therapy in cerebrovascular disorders

Progress in Cardiovascular Diseases

Volumn 34, Issue 4, 1992, Pages 235-262

  Levine, Steven R ^a,b   Brott, Thomas G ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANCROD; DICOUMAROL; FIBRINOLYTIC AGENT; HEPARIN; PLASMIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

CEREBROVASCULAR DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RECANALIZATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

ANCROD; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; HUMAN; STREPTOKINASE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; URINARY PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0026531144     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/0033-0620(92)90020-Z     Document Type: Article

References (234)

1. Thrombolytic therapy for stroke
2. Safety and potential efficacy of tissue plasminogen activator (tPA) for stroke
3. An open safety/efficacy trial of rt-PA in acute thromboembolic stroke: Final report
4. Cerebral angiography in acute cerebral infarction
5. Thrombosis and cerebrovascular disease
6. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours
7. Identification and entry of the patient with acute cerebral infarction
8. Early treatment for acute ischemic stroke
9. Brain tolerance to middle cerebral artery occlusion during hypotension in primates
10. Selective vulnerability of the brain: New insights into the pathophysiology of stroke
11. Temporary occlusion of the middle cerebral artery in the monkey: Clinical and pathological observations
12. Sequential metabolic changes in rat brain following middle cerebral artery occlusion: A 2-deoxyglucose study
13. Thresholds in cerebral ischemia: the ischemic penumbra
14. Viewing stroke pathophysiology: Analysis of contemporary methods
15. Thrombolytic therapy in Japan: Urokinase infusion for acute myocardial infarction
16. Special Report The thrombolysis in myocardial infarction (TIMI) trial
17. Middle cerebral artery occlusion: Correlation of computed tomography and angiography and clinical outcome
18. Occlusion of the middle cerebral artery. An experimental study
19. Thrombolysis and stroke: Past and future
20. Tissue plasminogen activator
21. Thrombolytic therapy in the eighties
22. Biochemical and clinical aspects of thrombolysis
23. Thrombolytic therapy Current status
24. Thrombolytic therapy: Current status
25. Platelets and thrombolytic therapy
26. Biochemical pharmacology and therapeutic aspects of thrombolytic agents
27. Thrombolytic treatment in cerebrovascular thrombosis
28. Controlled clinical trials of cerebral thrombolysis: A voice from the past
29. Anticoagulants plus streptokinase therapy in progressive stroke
30. Therapeutic thrombolysis in cerebral thrombembolism. Randomized evaluation of intravenous streptokinase
31. Therapeutic thrombolysis
32. Controlled clinical trials of cerebral thrombolysis: A voice from the past
33. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents
34. Early experience with fibrinolysin
35. The use of plasmin in humans
36. The use of plasmin in the treatment of intravascular thromboses
37. A pilot study of urokinase therapy in cerebral infarction
38. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion
39. NIH Consensus Conference Thrombolytic therapy in treatment
40. Blood hypercoagulability in acute cerebrovascular syndromes: Its control with urokinase therapy
41. Thrombolysis with fibrinolysin in cerebral arterial occlusion
42. Thrombolysis with fibrinolysis in cerebral arterial occlusion: The role of angiography
43. Embolism of the cerebral arteries
44. Treatment of cerebrovascular thrombosis with fibrinolysin
45. Fibrinolysin therapy in thrombotic diseases of the nervous system
46. Streptokinase cerebral vascular disease and triplets
47. Lysis of intracerebral thromboembolism with fibrinolyin: Report of a case
48. Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: Treatment by thrombolysin
49. Indications des thrombolytiques au cours des accidents vasculaires cerebraux thrombosants traites par ailleurs par O.H.B. (2ATA)
50. Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke
51. Hemostatic markers in acute stroke
52. Fibrinolytic agents: Are they feasible for stroke therapy
53. Local intraarterial fibrinolysis in the carotid territory
54. Resuscitation of the monkey brain after incomplete ischemia I Physiological and morphological observations
55. Lokale Fibrinolysetherapie bei Basilaris-thrombose
56. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease
57. Local intraarterial fibrinolytic therapy in inaccessible internal carotid occlusion
58. Survey of progress: Vascular recanalizing techniques in interventional neuroradiology
59. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease
60. Interventional neuroradiology: Local intraarterial fibrinolysis in acute verebrobasilar occlusion: Technical developments and recent results
61. t-PA and scupa: New concepts in the treatment of acute stroke
62. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model
63. Thrombolytic therapy in cerebrovascular disease stroke
64. Thrombolytic therapy in stroke: Possibilities and hazards
65. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A Pilot Study
66. Evoked potential monitoring during acute occlusion of the basilar artery and selective local thrombolytic therapy
67. Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis-dose-finding study by means of multicenter double-blind comparison
68. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction
69. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease
70. Retrospective study on the efficacy of using urokinase therapy
71. Controlled trial of Ancrod in ischemic stroke
72. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery
73. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis
74. A dose-escalation safety study of intravenous tissue plasminogen activator in patients treated from 90 to 180 minutes from onset of acute ischemic stroke
75. Double-blind, placebo controlled trial of recombinant tissue plasminogen activator (rt-PA) in acute carotid stroke
76. Ancrod causes rapid thrombolysis in patients with acute strokes
77. Hemorrhagic infarct of the brain without a re-opening of the occluded arteries in cardioembolic stroke
78. Acute vertebral basilar thrombosis: Angiologic-clinical comparison and therapeutic implications
79. Fibrinolysis of basilar artery thrombosis
80. Thrombus localization with emergency cerebral computed tomography
81. Lysis of basilar artery occlusion with tissue plasminogen activator
82. Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation
83. Clinical efficacy of urokinase in the treatment of cerebral thrombosis: Multicenter double-blind study in comparison with placebo
84. Thrombolytic therapy of cerebrovascular occlusive disease
85. Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-blind study
86. Clinical features of urokinase (60000 units/day) on cerebral infarction Comparative study by means of multicenter double-blind test
87. A significance of urokinase treatment in acute cerebral infarction: Assessment from neurological signs and CT findings
88. Thrombolytic therapy for thromboembolism of vertebrobasilar artery
89. Intracranial thrombolysis via a catheter embedded in the clot
90. Thrombolytic therapy and posterior circulation extracranial-intracranial bypass for acute basilar artery thrombosis. Case report
91. Recombinant tissue plasminogen activator in two patients with basilar artery occlusion
92. Local recombinant tissue plasminogen activator to clear cerebral artery thrombosis development soon after surgery
93. Vascular recanalizing techniques in the hind brain
94. In situ fibrinolysis in supra-aortic main vessels
95. Transthrombus bolus of fibrinolytic agents
96. Factors delaying evaluation of acute stroke
97. Blood pressure during the 1st hours of acute focal cerebral ischemia
98. Cerebral embolism: Angiographic observation on spontaneous clot lysis
99. Angiographic manifestations in post-recanalized cerebral infarction
100. Timing of autopsy. Confirmed hemorrhagic infarction with reference to cardioembolic stroke
101. Special problems associated with surgical and thrombolytic treatment of strokes
102. Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke
103. Cerebrovascular complications of streptokinase infusion
104. Effect of intravenous APSAC on mortality after acute myocardial infarction Preliminary report of a placebo-controlled clinical trial
105. Intracranial hemorrhage following thrombolysis with tissue plasminogen activator
106. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis
107. Putaminal haemorrhage after recanalization of an embolic MCA occlusion treated with tissue plasminogen activator
108. Update for the thrombolysis in myocardial infarction trial
109. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction
110. Stroke in patients treated with thrombolytic therapy for acute myocardial infarction. The thrombosis in myocardial infarction clinical trial and a review of placebo-controlled trials
111. Thrombolysis and Angioplasty in Myocardial Infarction Study Group Hemorrhage complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
112. Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment
113. GISSI-2 A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction
114. The Anglo-Scandinavian study of early thrombolysis (ASSET)
115. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction
116. Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment
117. Fatal streptokinase-induced intracerebral hemorrhage in cerebral amyloid angiopathy
118. Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator
119. Study of three drugs favors cheapest
120. Anticoagulant and thrombolytic therapy for cerebral embolism of cardiac origin
121. Errors and pitfalls in intraarterial thrombolytic therapy
122. Acute management of intracranial hemorrhage in patients receiving thrombolytic therapy: Case reports
123. Thrombolysis and stroke
124. Stroke complicating thrombolytic therapy of acute myocardial infarction
125. Intracerebral hemorrhage after rt-PA and heparin for acute myocardial infarction: The TIMI II pilot and randomized trial combined experience
126. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alterplase and streptokinase with or without heparin
127. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism
128. Long term effects of intravenous thrombolysis in acute myocardiol infarction Final report of the GISSI study
129. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
130. Intracranial hemorrhage after rt-PA and heparin for acute myocardial infarction—The TIMI II pilot and randomized combined experience
131. Safety of tissue plasminogen activator (moderator M.L. Dyken)
132. Stroke in the GISSI trial
133. Morphological responses of cerebral tissues to temporary ischemia
134. Early and late mechanisms of increased vascular permeability following experimental cerebral infarction
135. Racial differences in response to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrinogenolysis in blacks
136. Risk factor for hemorrhagic and ischemic stroke in myocardial infarct patients treated with tissue plasminogen activator
137. Thrombolysis and stroke in clinical practice: Past, present, and future
138. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management
139. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke
140. Incidence of cerebral hemorrhage after antifibrinolytic treatment for embolic stroke
141. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits
142. Effect of intraarterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits
143. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long-term prognosis
144. Successful treatment of posthetic heart-valve thrombosis with high short-term doses of streptokinase
145. Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator
146. Fibrinolytic treatment of thrombus on prosthetic heart valves
147. Plasminogen activator and cerebral infarction
148. Multiple microemboli after disintegration of clot during thrombolysis for acute myocardial infarction
149. Fatal ischemic brain edema after early thrombolysis with tissue plasminogen activator in acute stroke
150. Cerebral infarction and fibrinolytic agents
151. Streptokinase clot lysis in acute occlusions of the cranial circulation: Study in rabbits
152. Rapid fibrinolysis at different time intervals in a canine model of acute stroke
153. Thrombolytic therapy with urokinase and prourokinase in a canine model of acute stroke
154. Thrombolysis of cerebral thromboembolism by urokinase in an animal model
155. Hemorrhagic complications of thrombolytic therapy in experimental stroke
156. Experimental thromboembolic stroke studied by position emission toriography Immediate versus delayed reperfusion by fibrinolysis
157. Intracerebral hemorrhage: TPA versus streptokinase thrombolytic therapy
158. Streptokinase treatment versus calcium overload blockade in experimental thromboembolic stroke
159. Tissue plasminogen activator reduces neurological damage after cerebral embolism
160. Thrombolytic therapy for stroke
161. Intracerebral hemorrhage following r-tPA infusion in a private stroke model
162. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia
163. Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator
164. Mitigation of evolving cortical infarction in rats by recombinant tissue plasminogen activator following photochemically induced thrombosis
165. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke
166. Evaluation of recombinant tissue plasminogen activator in embolic stroke
167. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model
168. Selective embolization and clot dissolution with tPA in the interval carotid artery circulation of the rabbit
169. Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke
170. Thrombolytic therapy in experimental focal cerebral ischemia
171. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator
172. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction
173. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits
174. Differential effect of t-PA induced thrombolysis in the CNS and systemic arteries
175. The effects of a new tissue plasminogen activator analogue Fb-Fb-CF, on cerebral reperfusion in a rabbit embolic stroke model
176. Delayed treatment with a t-PA analogue and streptokinase in a rabbit embolic stroke model
177. Early and delayed thrombolytic therapy in rabbit cerebral embolization model using a t-PA analogue
178. Enhancement of thrombolysis with tissue-type plasminogen activator by pre-treatment with heparin
179. Effect of heparin-urokinase on brain damage induced by cerebral ischemia in dogs
180. The use of anti coagulants and thrombolytic agents in occlusive retinal vascular disease
181. Thromboembolic disorders of the eye
182. Central retinal vein thrombosis: Serial treatment with defibrination, aspirin and plasminotropic drugs
183. Fibrinolysin therapy in thrombotic diseases of the nervous system
184. Treatment of cerebrovascular thrombosis with fibrinolysin Preliminary Report
185. Treatment of central retinal vein thrombosis with ancrod
186. Clinical radiological correlation in cerebral venous occlusive disease
187. Streptokinase therapy and cavenous sinus thrombosis
188. Streptokinase in central retinal vein occlusion: A controlled clinical trial
189. Superior sagittal sinus thrombosis
190. Thrombose des sinus veineux intra-craniens (apropos de 22 cas)
191. Heparinurokinase treatment in aseptic dural sinus thrombosis
192. Diagnostic and therapeutic approach to cerebral venous thrombosis
193. Treatment of dural sinus thrombosis with local urokinase infusion
194. Extensive dural sinus thrombosis treated by surgical removal and local streptokinase infusion
195. Endovascular thrombolytic therapy for dural sinus thrombosis
196. Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus
197. Local urokinase treatment for spontaneous intracerebral hematoma
198. Lysis of intracranial hematomas with urokinase in a rabbit model
199. Thrombolytic therapy of intracerebral hematomas
200. Efficacy and safety of tissue plasminogen activator
201. CT-guided stereotoxic evacuation of hypertensive intracerebral hematomas
202. CT-guided stereotactic fibrinolysis of spontaneous and hypertensive cerebellar hemorrhage: Long-term results
203. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm
204. Intrathecal thrombolytic therapy in the prevention of vasospasm following subarachnoid hemorrhage
205. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: Dosage study in a primate model and review of the literature
206. Fibrinolysis in the central nervous system
207. Fibrinolytic activity of the spinal fluid and meninges
208. Lysis of blood and experimental treatment of subarachnoid hemorrhage
209. Intrathecal irrigation with urokinase in ruptured cerebral aneurysm cases. Basic studies and clinical applications
210. “Scavenger surgery” for subarachnoid hemorrhage (II) continuous ventriculocisternal perfusion using artificial cerebrospinal fluid with urokinase
211. Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin
212. Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin
213. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage
214. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH
215. Prevention of vasospasm: Cisternal irrigation therapy with urokinase and ascorbic acid
216. Prevention of post-operative vasospasm by cisternal irrigation
217. Cisternal recombinant tPA administration in aneurysmal subarachnoid hemorrhage
218. Injection of tissue plasminogen activator to prevent delayed vasospasm
219. Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. Canine intraventricular blood clot model
220. Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase
221. Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and post-hemorrhagic hydocephalus
222. Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase
223. Lysis of intraventricular hematoma with tissue plasminogen activator
224. Session 3: Thrombolytic therapy for acute stroke
225. The investigational use of tPA for stroke
226. Effect of tissue plasminogen activator on microcirculation and size of infarction following MCA occlusion in cat
227. Neurological deficit and cerebral infarction after temporary middle cerebral artery occlusion in unanesthetized cats
228. The effect of spontaneous reperfusion on metabolic function in early human cerebral infarcts
229. A perspective on the future of thrombolytic stroke therapy
230. Investigational use of t-PA in acute stroke
231. Intraarterial thrombolytic therapy in acute stroke
232. Local low dose intraarterial thrombolytic therapy: The risk of stroke or major hemorrhage
233. Heart drug shows promise in strokes
234. With advent of new heart drugs, delay in seeking help is major killer